UBS Group
NBP

UBS Group’s NovaBridge Biosciences American Depositary Shares NBP Stock Holding History

UBS Group’s Portfolio NBP Stock Details NBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$588K Buy
301,780
+238,239
+375% +$486K ﹤0.01% 6129
2026
Q1 		$156K Sell
63,541
-118,235
-65% -$396K ﹤0.01% 6771
2025
Q4 		$723K Sell
181,776
-113,302
-38% -$501K ﹤0.01% 5839
2025
Q3 		$1.12M Buy
295,078
+110,233
+60% +$374K ﹤0.01% 5479
2025
Q2 		$447K Sell
184,845
-133,701
-42% -$181K ﹤0.01% 6101
2025
Q1 		$262K Buy
318,546
+215,492
+209% +$205K ﹤0.01% 6351
2024
Q4 		$87.6K Buy
+103,054
New +$115K ﹤0.01% 6960
2024
Q3 		– Sell
-12,514
Closed -$20.9K – 9763
2024
Q2 		$20.9K Buy
12,514
+11,183
+840% +$20K ﹤0.01% 7276
2024
Q1 		$2.48K Sell
1,331
-13,948
-91% -$25.7K ﹤0.01% 7895
2023
Q4 		$29K Sell
15,279
-543,274
-97% -$812K ﹤0.01% 6861
2023
Q3 		$737K Buy
558,553
+20,894
+4% +$45.9K ﹤0.01% 4355
2023
Q2 		$1.61M Buy
537,659
+6,465
+1% +$20.8K ﹤0.01% 3750
2023
Q1 		$1.84M Sell
531,194
-12,278
-2% -$59.5K ﹤0.01% 3523
2022
Q4 		$2.27M Buy
543,472
+432,657
+390% +$1.64M ﹤0.01% 3266
2022
Q3 		$444K Sell
110,815
-108,344
-49% -$822K ﹤0.01% 4441
2022
Q2 		$2.48M Buy
219,159
+116,918
+114% +$1.4M ﹤0.01% 2964
2022
Q1 		$1.66M Buy
102,241
+31,577
+45% +$809K ﹤0.01% 3619
2021
Q4 		$3.35M Sell
70,664
-23,638
-25% -$1.42M ﹤0.01% 3256
2021
Q3 		$6.84M Sell
94,302
-75,692
-45% -$5.47M ﹤0.01% 2356
2021
Q2 		$14.3M Buy
169,994
+169,334
+25,657% +$11.2M ﹤0.01% 1752
2021
Q1 		$32K Buy
660
+64
+11% +$3.47K ﹤0.01% 6956
2020
Q4 		$28K Sell
596
-17,628
-97% -$694K ﹤0.01% 6690
2020
Q3 		$857K Buy
+18,224
New +$601K ﹤0.01% 3755
2020
Q2 		– Sell
-1,985
Closed -$26K – 8136
2020
Q1 		$26K Buy
+1,985
New +$24.8K ﹤0.01% 6326

Other funds holding NBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACM
AIHC Capital Management Central $104M AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group's NBP Position: Q2 2026 in Review

UBS Group increased its NovaBridge Biosciences American Depositary Shares (NBP) stake by 375% in Q2 2026, buying an estimated $486K and bringing the position to 301,780 shares worth $588K. The position accounts for ﹤0.01% of the portfolio, ranked #6129.

UBS Group first reported a position in NBP in Q1 2020 and has held it in 24 quarters since. The position peaked at $14.3M in Q2 2021. 49 funds tracked by Wall St. Rank hold NBP as of Q2 2026.

  • UBS Group held 301,780 shares of NovaBridge Biosciences American Depositary Shares worth $588K as of Q2 2026.
  • UBS Group bought 238,239 NovaBridge Biosciences American Depositary Shares shares in Q2 2026, an estimated $486K.
  • NovaBridge Biosciences American Depositary Shares made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6129 holding.
  • UBS Group first reported a position in NovaBridge Biosciences American Depositary Shares in Q1 2020 and has held it in 24 quarters since.
  • UBS Group's NovaBridge Biosciences American Depositary Shares position peaked at $14.3M in Q2 2021.
  • 49 funds tracked by Wall St. Rank held NovaBridge Biosciences American Depositary Shares as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.